Erythropoietin in the treatment of anemia in chronic infectious, inflammatory, and malignant diseases.
The anemia associated with chronic infectious, inflammatory, and malignant diseases is characterized by a blunted erythropoietin response; for any given decrease in hemoglobin or hematocrit, the increase in serum or plasma erythropoietin is less than would be found in an equally anemic patient with iron deficiency. This observation provides a rationale for the use of recombinant human erythropoietin in the treatment of the anemia in these diseases. During the past year, new information has been reported on the pathophysiology of erythropoiesis in chronic infectious, inflammatory, and neoplastic diseases, and on the use of recombinant human erythropoietin for this anemia. This article reviews these developments.
Means
R T
RT
University of Cincinnati College of Medicine, Ohio, USA.
D000740:Anemia / Q000188:drug therapy*; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004921:Erythropoietin / Q000627:therapeutic use*; D006801:Humans; D007239:Infections / Q000150:complications*; D007249:Inflammation / Q000150:complications*; D009369:Neoplasms / Q000150:complications*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin